The size of the Vaccine Adjuvant Market in the Middle East & Africa is estimated to be worth USD 106 million by 2028 from USD 64.09 million in 2023, growing at a CAGR of 10.6% from 2023 to 2028.
The Adjuvants are immunological or pharmacological agents that support synergizing and leading the adaptive immune response to vaccine agents. The problem with unadulterated recombinant or engineered antigens used as a part of innovative vaccinations is that they are far less immunogenic than more experienced style lives or slaughtered complete living being antibodies. Therefore, it has made an essential requirement for improved and more powerful adjuvants for use in these immunizations.
The growth of this region owes to factors such as growing research and development expenditure and acquisitions that propel the market. However, lack of awareness, less prominence on research and development activities, and inadequate medical facilities are estimated to hamper the market growth in this region.
This research report on the MEA vaccine adjuvant market has been segmented and sub-segmented into the following categories:
By Route Of Administration:
By Mechanism Of Action:
Regionally, Middle-East is estimated to dominate the region's vaccine adjuvant market in the forecast period. UAE Vaccine Adjuvant market leads the MEA market owing to the number of steps taken by the government towards the vaccination in children as there is an average increase of diseases and the growing number of awareness programs for promoting the treatments which drive the vaccine adjuvant market growth during the analysis period. However, the high cost of vaccine development is likely to hamper the market.
UAE follows Saudi Arabia, South Africa, and the Rest of MEA countries in having a high share of the market during the period. However, a lack of poor reimbursement policies from a few governments may restrict the adjuvant vaccine market.
KEY MARKET PLAYERS:
Companies playing an active role in the MEA vaccine adjuvant market profiled in this report are MPV Technologies, Avanti Polar Lipids, Novavax Inc. Brenntag Biosector, SEPPIC, Agenus, Inc., Invivogen, SPI Pharma, Inc., CSL Limited, and OZ Biosciences.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com